hexocyclium methylsulfate

Trade name: tral

Small moleculeapproved

Approved

Feb 13, 1957

Hexocyclium is an old anticholinergic drug. Hexocyclium is an antimuscarinic. Hexocyclium in therapeutic doses produces a prolonged reduction of gastric acidity. It was used for the treatment of peptic ulcer. Hexocyclium is effective for the control of cramps and diarrhea in cases of irritable bowel syndrome. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1950s

  1. Feb 13, 1957

    AbbVie — Earliest FDA Approval

  2. Feb 13, 1957

    AbbVie — NDA Secondary Org

  3. Feb 13, 1957

    AbbVie — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedFeb 13, 1957

Chemistry & pharmacology

Loading structure…

SMILES

C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1
Mol. weight
317.5 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 4-(2-cyclohexyl-2-hydroxy-2-phenethyl)-1,1- dimethylpiperazinium
  • hexociclium
  • hexocyclium
  • hexocyclium
  • hexocyclium
  • hexocyclium
  • hexocyclium
  • hexocyclium
  • hexocyclium
  • hexocyclium
  • hexocyclium methylsulfate
  • hexocyclium methylsulfate
  • hexocyclium methylsulfate
  • hexocyclium methylsulfate
  • hexocyclium methylsulfate
  • hexocyclium methyl sulfate
  • hexocyclium methyl sulfate
  • hexocyclium methyl sulfate
  • hexocyclium methyl sulfate
  • hexocyclium methyl sulfate
  • hexocyclium metilsulfate
  • hexocyclium metilsulfate
  • hexocyclium metilsulfate
  • tral
  • tral
  • tral

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
AbbVieFor profitNDA2Feb 13, 1957
AbbVieFor profitNDAFeb 13, 1957